Contraception required
Effective contraception is required during treatment.
Leaflet MYFORTIC 360mg gastro-resistant tablets
- Product code:
- W70689003
- Quantity:
- 120
- Indicated for:
- prevention of transplant rejection
- Route of administration:
- oral
- Substance:
- mycophenolate (immunomodulator)
- ATC
- L04AA06 — Antineoplastic and immunomodulating agents | Immunosuppressants | Immunosuppressants | Selective immunosuppressants
Precautions:
Contraindicated during pregnancy
Do not use this medicine during pregnancy.
Avoid live vaccines
Avoid live vaccines during treatment if contraindicated.
Immunosuppression / infection risk
This medicine may increase the risk of infections.
Myelosuppression / agranulocytosis
This medicine may lower blood cell counts.
Teratogenic / fetal risk
This medicine may affect fetal development.
Mycophenolate is an immunosuppressive medication used to prevent organ rejection in transplant recipients, such as kidney, liver, or heart transplants. It is often used in combination with other immunosuppressive drugs, such as cyclosporine and corticosteroids. Mycophenolate works by inhibiting the proliferation of T and B lymphocytes, thereby reducing the immune response against the transplanted organ.
Mycophenolate is available as mycophenolate mofetil (MMF) or mycophenolate sodium (MPS), both of which are taken orally, usually twice daily, as directed by a doctor. The exact dosage depends on the type of transplant and the patient’s condition.
Common side effects include nausea, diarrhea, vomiting, abdominal pain, and infections, as the medication suppresses the immune system. Other side effects may include anemia, leukopenia (low white blood cell count), and an increased risk of severe or opportunistic infections.
Mycophenolate is contraindicated in pregnant women, as it can cause severe birth defects. Women of childbearing age must use effective contraception during treatment and for several weeks after stopping the medication. Regular monitoring is essential to detect potential side effects and adjust the dosage if necessary.
Mycophenolate is available as mycophenolate mofetil (MMF) or mycophenolate sodium (MPS), both of which are taken orally, usually twice daily, as directed by a doctor. The exact dosage depends on the type of transplant and the patient’s condition.
Common side effects include nausea, diarrhea, vomiting, abdominal pain, and infections, as the medication suppresses the immune system. Other side effects may include anemia, leukopenia (low white blood cell count), and an increased risk of severe or opportunistic infections.
Mycophenolate is contraindicated in pregnant women, as it can cause severe birth defects. Women of childbearing age must use effective contraception during treatment and for several weeks after stopping the medication. Regular monitoring is essential to detect potential side effects and adjust the dosage if necessary.
General data about MYFORTIC 360mg
- Substance:
- mycophenolate
- Date of latest medicines list:
- 01-06-2026
- Product code:
- W70689003
- Concentration:
- 360mg
- Pharmaceutical form:
- gastro-resistant tablets
- Quantity:
- 120
- Product type:
- Original
- Price:
- 714.00 RON
- Prescription status:
- P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.
Pharmaceutical forms available for mycophenolate
Concentrations available for mycophenolate
- 180mg
- 1g/5ml
- 360mg
- 500mg
Compensation lists for MYFORTIC 360mg Europharm
NHP 9.4 (C2) - Kidney transplant, combined kidney and pancreas transplant
- Price
- 714.00 RON
- Copayment
- 714.00 RON
- Patient
- 0.00 RON
NHP 9.7 (C2) - Outpatient treatment of transplant patients
- Price
- 714.00 RON
- Copayment
- 714.00 RON
- Patient
- 0.00 RON